🔗 Share this article

Given that the United States continues making historic changes to its vaccination recommendations, a particular individual has surfaced in a surprising turn: Høeg, a Danish American sports physician and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccines throughout the pandemic and has concentrated on alleged deaths after Covid vaccination in her short tenure at the Food and Drug Administration.

Proposed Changes to Childhood Immunization Program

Public health authorities were set to reveal radical changes to the childhood vaccine schedule earlier this month, bringing the US with Denmark’s immunization schedule, according to reports – a significant shift that would place the US at odds with a large portion of the international standard with no evidence for public health gain. The planned update has been postponed until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is listed to speak at the meeting. She was just designated interim head of the FDA’s CDER, the fifth individual to run the center this year.

A New Direction at the Regulatory Body

This interim role may indicate a closer partnership between the drug and vaccine centers as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a renewed priority upon reevaluating already-approved immunizations at the FDA.

The new acting director has often pushed for ending specific pediatric vaccine recommendations in the US to become more like Denmark, a nation with nationalized medicine and a population roughly the population of the state of Wisconsin.

To date comments, she has continued to focus on vaccines – usually the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Questions Over Background

Høeg has no apparent experience in drug development, oversight or management, which has been standard for previous directors of the biologics center. She has served at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for running the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in leading a major agency. She lacks background in industry regulation.”

Former commissioners of the center would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that previous people who ran the center have had.”

The drug center has an immense portfolio at the FDA, Woodcock stated.

“Many people just zeroes in on the new drug program, but the generic program clears thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and more, and every single one need to be looked after,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

There is also, a substantial leadership component to the job, which manages in excess of 5,000 employees. “It’s a enormous administrative position, if you execute it properly,” the former official added.

Agency Reaction and Controversial Programs

Regarding questions about Dr. Høeg's credentials and whether this assignment represents more teamwork among FDA leaders on immunizations, a press secretary said that the “concerns are based on flawed presumptions”.

“This background matches the duties of her role,” the representative said, citing the time Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the agency head's controversial priority voucher program, a contentious one-day drug-approval program that allegedly concerned her preceding directors. “By what process are these drugs being chosen for this voucher program? Who makes the choices?” Howard questioned. “There is a lot of lack of transparency going on at the agency right now.”

Overall, he remarked, “the agency appears to be shifting towards more relaxed regulations of all drugs, except for vaccines.”

Public History on Immunizations

With vaccines, Dr. Høeg has a more established, if troubling, track record, Howard have noted. She released a analysis using non-validated public submissions to estimate the frequency of myocarditis after COVID-19 immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who allegedly have altered data to imply COVID-19 vaccinations are more dangerous than they are.

Among her “desired changes” for the current federal leadership encompassed revising rules for new vaccines and discontinuing “non-essential” vaccines, she said following the vote on a podcast. At the FDA, Dr. Høeg has according to sources proposed barring adolescent males from getting COVID-19 vaccines.

“She’s an complete ideologue who commences with her preconceived notions and reverse-engineers to retrofit the data in a very disingenuous, dishonest way,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Høeg became part of other dissenters, {like|